SGS France – FDA 483, Aug 29, 2025
An FDA inspection of SGS France Life Sciences in Saint Benoit, France, revealed significant deficiencies in their bioanalytical facility's method validation and study sample activities. Observations included an analytical method lacking sufficient specificity, incomplete reporting of rejected analytical sequences, and non-contemporaneous documentation of experiments. Additionally, the firm failed to follow established SOPs regarding deviation documentation, indicating systemic issues with data integrity and quality control.
ID · 6edc34f4-69ed-480c-abd7-a70c0cb64de4
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.